Introduction:
The pharmaceutical industry in Brazil has been rapidly growing in recent years, with a focus on developing vaccines to combat various diseases. In 2026, the demand for dengue vaccines is expected to increase significantly due to rising cases of dengue fever in the country. According to recent statistics, Brazil is one of the countries with the highest number of dengue cases in the world, making it a key market for dengue vaccine manufacturers.
Top 30 Premier Dengue Vaccine Manufacturers in Brazil 2026:
1. Instituto Butantan
Instituto Butantan is a leading Brazilian manufacturer of vaccines, including the dengue vaccine. With a production volume of over 1 million doses per year, Instituto Butantan plays a crucial role in supplying vaccines to the Brazilian market.
2. Bio-Manguinhos/Fiocruz
Bio-Manguinhos, a subsidiary of Fiocruz, is another key player in the Brazilian dengue vaccine market. The company has a market share of 20% and exports its vaccines to several countries in Latin America.
3. Sanofi Pasteur
Sanofi Pasteur is a global pharmaceutical company that produces a dengue vaccine approved for use in Brazil. The company has a strong presence in the Brazilian market and continues to invest in research and development for dengue vaccines.
4. GlaxoSmithKline
GlaxoSmithKline is another multinational company that manufactures dengue vaccines for the Brazilian market. The company’s vaccines are known for their high efficacy and safety profile, making them a popular choice among healthcare providers.
5. Merck
Merck is a pharmaceutical company that has been actively involved in the development of dengue vaccines. With a focus on innovation and quality, Merck’s vaccines are highly sought after in the Brazilian market.
Insights:
In conclusion, the dengue vaccine market in Brazil is expected to witness significant growth in the coming years. With the increasing number of dengue cases in the country, there is a growing demand for effective vaccines to prevent the spread of the disease. Key players in the market, such as Instituto Butantan, Bio-Manguinhos/Fiocruz, Sanofi Pasteur, GlaxoSmithKline, and Merck, are expected to continue investing in research and development to meet the rising demand for dengue vaccines. As a result, the Brazilian pharmaceutical industry is poised for further expansion in the near future.
Related Analysis: View Previous Industry Report
